{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.98","value":"-0.8"},{"groupId":"OG001","spread":"1.75","value":"-1.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"173"},{"groupId":"OG001","value":"182"}],"units":"Participants"}],"description":"Enthesitis will be assessed using the Leeds Enthesitis Index (LEI). The LEI was developed to assess enthesitis in participants with PsA, and evaluates the presence (score of 1) or absence of pain (score of 0) by applying local pressure to Lateral elbow epicondyle, left and right, Medial femoral condyle, left and right, and Achilles tendon insertion, left and right. LEI scores ranging from 0 (0 sites with tenderness) to 6 (worst possible score; 6 sites with tenderness).","dispersionType":"Standard Deviation","groups":[{"description":"Participants received intravenous infusions of placebo at Weeks 0, 4, 12 and 20.","id":"OG000","title":"Placebo"},{"description":"Participants were randomized to receive intravenous infusions of golimumab 2 mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52. At Week 24, participants received a placebo infusion to maintain the blind.","id":"OG001","title":"Golimumab"}],"paramType":"MEAN","populationDescription":"Population included all randomized participants with Enthesitis at Baseline. Here \"N\" (number of participants analyzed) signifies the number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 14","title":"Change From Baseline in Leeds Enthesitis Index (LEI) at Week 14 in Participants With Enthesitis at Baseline","type":"SECONDARY","unitOfMeasure":"units on a scale"}